Groche D, Hoeno W, Hoss G, Vogt B, Herrmann Z, Witzigmann A
Roche-Diagnostics GmbH, D-68305 Mannheim, Germany.
Clin Lab. 2003;49(11-12):657-61.
The measurement of HbA1c is meanwhile well established as the most important parameter in clinical chemistry for monitoring the long term metabolic control of diabetic patients. However, the comparability of HbA1c values obtained by different methods in different laboratories and different countries is limited since there was no internationally agreed reference method available. Additionally the % HbA1c values, based on the most common DCCT values are too high due to well known non specificity of the DCCT standardization protocol. Recently a new reference method for the determination of HbA1c was developed and has been approved by the IFCC as the future basis for the worldwide standardization of HbA1c routine assays. The two routine methods from Roche Diagnostics (both based on the immunoturbidimetric determination of the stable glucose adduct to the N-terminal group of the hemoglobin beta chain, Roche-Hitachi/Tina-quant [a] and COBAS INTEGRA) are directly standardized against this new reference method. Both routine methods are based on a two step approach: in a first step the total Hb is quantified by a colorimetric method and in a second step the stable glucose adduct to the N-terminal group of the hemoglobin beta chain is quantified by immunoturbidity (HbA1c mass). Consequently, first the standardization of the total Hb assay was reconfirmed by method comparisons against the cyanomethemoglobin reference method. Second, the standardization of the HbA1c mass was done by running method comparisons against the new IFCC reference method. The resulting new calibrator values for HbA1c [mass] and total Hb [mass] allow a direct estimation of % HbA1c according to IFCC just by calculating the HbA1c [mass]/total Hb [mass] ratio. Good linear correlations were obtained when comparing the routine methods against the new IFCC reference, indicating the high specificity of these immunological approaches. The following correlations are obtained: Hitachi / Tina-quant [a] (Y) versus IFCC reference method (X): Y = -0.031 + 1.009 x X; r = 0.995. COBAS INTEGRA (Y) versus IFCC reference method (X): Y = -0.156 + 1.006 x X; r = 0.997. Hitachi / Tina-quant [a] (Y) versus Integra (X); (both standardized according to IFCC): Y = 0.057 + 1.003 x X; r = 0.997. The HbA1c values obtained with this new IFCC standardization are significantly lower than the well known DCCT values. Due to the specificity of the immunological approach which is very close to the analyte as defined by the IFCC reference method, no further corrections of the obtained % HbA1c values are necessary. A slope/intercept correction formula is derived which allows the transformation of IFCC values into the DCCT numbers if requested.
同时,糖化血红蛋白(HbA1c)的测定已成为临床化学中监测糖尿病患者长期代谢控制的最重要参数。然而,由于缺乏国际公认的参考方法,不同实验室和不同国家采用不同方法获得的HbA1c值的可比性有限。此外,基于最常用的糖尿病控制与并发症试验(DCCT)值的HbA1c百分比值过高,这是由于DCCT标准化方案存在众所周知的非特异性。最近,一种用于测定HbA1c的新参考方法已被开发出来,并已被国际临床化学和检验医学联合会(IFCC)批准作为全球HbA1c常规检测标准化的未来基础。罗氏诊断公司的两种常规方法(均基于免疫比浊法测定血红蛋白β链N端基团的稳定葡萄糖加合物,罗氏日立/Tina-quant [a]和COBAS INTEGRA)直接根据这种新参考方法进行标准化。两种常规方法都基于两步法:第一步通过比色法对总血红蛋白进行定量,第二步通过免疫比浊法(HbA1c质量)对血红蛋白β链N端基团的稳定葡萄糖加合物进行定量。因此,首先通过与氰化高铁血红蛋白参考方法进行方法比较,重新确认了总血红蛋白检测的标准化。其次,通过与新的IFCC参考方法进行方法比较,完成了HbA1c质量的标准化。由此得到的HbA1c [质量]和总血红蛋白[质量]的新校准值允许仅通过计算HbA1c [质量]/总血红蛋白[质量]比值,直接根据IFCC估算HbA1c百分比。将常规方法与新的IFCC参考方法进行比较时,获得了良好的线性相关性,表明这些免疫方法具有高特异性。得到以下相关性:日立/Tina-quant [a](Y)与IFCC参考方法(X):Y = -0.031 + 1.009xX;r = 0.995。COBAS INTEGRA(Y)与IFCC参考方法(X):Y = -0.156 + 1.006xX;r = 0.997。日立/Tina-quant [a](Y)与Integra(X);(两者均根据IFCC标准化):Y = 0.057 + 1.003xX;r = 0.997。采用这种新的IFCC标准化获得的HbA1c值明显低于众所周知的DCCT值。由于免疫方法的特异性与IFCC参考方法定义的分析物非常接近,因此无需对获得的HbA1c百分比值进行进一步校正。推导了一个斜率/截距校正公式,如果需要,可以将IFCC值转换为DCCT数值。